MAR-TROSPIUM 20 MG
TROSPIUM CHLORIDE : 20 MG · DIN 02488353 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-TROSPIUM?
MAR-TROSPIUM 20 MG contains TROSPIUM CHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02488353, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Jun-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-TROSPIUM used for?
Mar-Trospium (trospium chloride) is indicated for: • the treatment of overactive bladder with symptoms of urge or mixed urinary incontinence, urgency, and urinary frequency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02488353 |
|---|---|
| Brand name | MAR-TROSPIUM |
| Generic / active ingredient | TROSPIUM CHLORIDE : 20 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD09 TROSPIUM |
| AHFS class | 86:12.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jun-2019 |
| Original market date | 2019-06-21 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code G04BD09 TROSPIUM. 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-TROSPIUM | 20 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02492717 |
| JAMP TROSPIUM | 20 MG | TABLET | JAMP PHARMA CORPORATION | DORMANT | DIN 02506661 |
| SANCTURA XR | 60 MG | CAPSULE (EXTENDED RELEASE) | ALLERGAN INC | CANCELLED POST MARKET | DIN 02339706 |
| TROSEC | 20 MG | TABLET | SUNOVION PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02275066 |
Who else supplies TROSPIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TROSPIUM appears in 18 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.